HR 9661 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
Expedited Access to Biosimilars Act
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Summary
- Amends biosimilar drug licensing requirements to make the default expectation that additional clinical efficacy studies are not required for approval.
- Requires the FDA to provide written justification if it determines that additional clinical studies assessing pharmacodynamics or efficacy are necessary for a biosimilar application.
- Requires the FDA to notify sponsors by the biosimilar development meeting date or within 60 days of application submission if additional clinical studies are determined to be necessary.
- Removes certain review requirements from the biosimilar licensure process.
- Applies to biosimilar applications submitted after the bill's enactment.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
2 cosponsors
Actions (2)
- Jul 14, 2026 Referred to the House Committee on Energy and Commerce. · house
- Jul 14, 2026 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Committee action
What happened to this bill in committee — the meetings where it was considered and every recorded vote taken on it.
Meetings where this bill was on the agenda
Full text
IN THE HOUSE OF REPRESENTATIVES
July 14, 2026
Mr. Langworthy (for himself and Ms. Schrier) introduced the following bill; which was referred to the Committee on Energy and Commerce
A BILL
To amend the Public Health Service Act to codify that the default expectation for licensure of biological products as biosimilar does not include clinical studies assessing pharmacodynamics or comparative clinical efficacy, and for other purposes.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Expedited Access to Biosimilars Act”.
SEC. 2. ASSESSMENT OF PHARMACODYNAMICS OR EFFICACY IN CLINICAL STUDIES REQUIRED FOR LICENSURE OF BIOLOGICAL PRODUCTS AS BIOSIMILAR.
(a) In General.—Section 351(k)(2)(A) of the Public Health Service Act (42 U.S.C. 262(k)(2)(A)) is amended—
(1) in clause (i)(I)—
(A) in item (bb)—
(i) by striking “item (aa) or (cc)” and inserting “item (aa), (cc), or (dd)”; and
(ii) by striking “and” at the end; and
(B) by striking item (cc) and inserting the following:
“(cc) an assessment of pharmacokinetics and immunogenicity (which may rely on, or consist of, a clinical pharmacokinetics study or studies or a study or studies described in item (aa) or (dd), as appropriate); and
“(dd) subject to clause
(iv), an additional clinical study or studies in 1 or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product;”; and
(2) by adding at the end the following:
“(iv) Limitation on requiring additional clinical study or studies.—The Secretary may only require an additional clinical study or studies described in clause (i)(I)(dd), including a study or studies that include an assessment of pharmacodynamics or efficacy, if the Secretary determines that such study or studies are necessary, in combination with the other studies described in clause (i)(I), to demonstrate biosimilarity and provides written notice of such determination to the sponsor of the proposed biosimilar biological product. Such written notice shall be provided not later than—
“(I) the date on which the Secretary grants a request for a biosimilar biological product development meeting from such sponsor, unless the Secretary describes in writing why an assessment of the need for such study or studies cannot be made at that time; or
“(II) if no request for a biosimilar biological product development meeting is submitted or if the Secretary was unable to make the assessment under subclause (I), the date that is 60 days after the date of the submission of an application under this subsection.”.
(b) Repeal of Requirement Relating To Conduct of Reviews.—Section 351(k)(5) of the Public Health Service Act (42 U.S.C. 262(k)(5)) is amended—
(1) by striking subparagraph (B); and
(2) by redesignating subparagraph (C) as subparagraph (B).
(c) Applicability.—The amendments made by subsection (a) shall apply with respect to an application submitted under section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) on or after the date of enactment of this Act. <all>
Comments